BUZZ-H.C. Wainwright starts coverage of Artiva Biotherapeutics with 'buy' rating

Reuters
2024-12-30
BUZZ-H<a href="https://laohu8.com/S/02403">.C</a>. Wainwright starts coverage of Artiva Biotherapeutics with 'buy' rating

** Brokerage H.C. Wainwright starts coverage of drug developer Artiva Biotherapeutics ARTV.O with "buy" rating and PT of $20

** PT represents an ~88% upside to stock's last close

** Co is testing its experimental drug, AlloNK, for an autoimmune disease called systemic lupus erythematosus $(SLE)$ in combination with antibodies Rituxan or Gazyva

** SLE is a condition where the immune system attacks the body's own tissues

** Brokerage notes "current treatment options do not effectively control disease progression"

** Says AlloNK costs less than $6,000 per patient for ARTV to produce, compared to ~$100,000 for auto-CAR T therapies

** Co has capacity to produce enough AlloNK for over 1,000 autoimmune patients annually, H.C. Wainwright says

** Brokerage expects AlloNK to launch by 2029 and forecasts sales to grow to $531 mln by 2031

** As of last close, stock has fallen ~34% YTD

(Reporting by Kamal Choudhury in Bengaluru)

((Kamal.Choudhury@thomsonreuters.com;))

免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。

热议股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10